التفاصيل البيبلوغرافية
| العنوان: |
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. |
| المؤلفون: |
Stephenson, Diane, Hill, Derek, Cedarbaum, Jesse M., Tome, Maria, Vamvakas, Spiros, Romero, Klaus, Conrado, Daniela J., Dexter, David T., Seibyl, John, Jennings, Danna, Nicholas, Timothy, Matthews, Dawn, Xie, Zhiyong, Imam, Syed, Maguire, Paul, Russell, David, Gordon, Mark Forrest, Stebbins, Glenn T., Somer, Ed, Gallagher, Jill |
| المصدر: |
Journal of Parkinson's Disease; 2019, Vol. 9 Issue 3, p553-563, 11p |
| مصطلحات موضوعية: |
PARKINSON'S disease, CLINICAL trials, PHOTON emission, POSITRON emission tomography, LITERATURE reviews |
| الشركة/الكيان: |
EUROPEAN Medicines Agency |
| مستخلص: |
As therapeutic trials target early stages of Parkinson's disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson's Consortium formally submitted documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson's Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT) scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress clinically from being exposed to novel test therapeutics. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Parkinson's Disease is the property of IOS Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
